Ryanodine receptor Inhibitors
1 drugsAbout Ryanodine receptor
The Ryanodine receptor (RyR) is a calcium channel crucial for excitation-contraction coupling in muscle cells, regulating muscle function by controlling calcium release from intracellular stores.
RyR is a drug target in the cardiovascular therapeutic area, though currently there is no genetic evidence directly linking it to specific diseases.
RYANODEX is the only FDA-approved drug targeting RyR, developed by EAGLE PHARMS; it is a small molecule approved in 2014 with 5 indications.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Ventricular Tachycardia with only 1 trials.
Top Ryanodine receptor Drugs
EAGLE PHARMS is the only company with an approved drug targeting RyR.
Low competition suggests high barriers to entry or limited perceived market opportunity for RyR-targeting drugs.
Ryanodine receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Ryanodine receptor, using small molecule modality.
The lack of diverse modalities represents a whitespace opportunity for novel biologics targeting RyR.
Ryanodine receptor Clinical Trials 11 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 2 | 0 | 1 | 100% |
| Phase 2 | 7 | 4 | 2 | 1 | 67% |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Ryanodine receptor Drug Approval Timeline (2014 - 2014)
The first and only drug, RYANODEX, was approved in 2014.
The single approval in 2014 indicates potential saturation or challenges in developing further RyR-targeting therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (14 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 16 clinical trials targeting Ryanodine receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities